Efficacy and Safety of Bone Marrow Concentrate for Osteoarthritis of the Hip; Treatment Registry Results for 196 Patients

Methods Setting and participantsData were accessed from a private autologous cellular treatment registry.The database is the result of an ongoing prospective survey system that was designed to follow the safety and efficacy of various Abstract Introduction: We investigated the efficacy and safety of autologous bone marrow concentrate (BMC) for the treatment of symptomatic hip osteoarthritis.Methods: Treatment registry data for 216 hips treated among 196 patients who underwent a BMC procedure for hip osteoarthritis (OA) were analyzed.Data regarding adverse events (AEs), subjective percentage improvement, Oxford Hip Scores (OHS), and numeric pain scale (NPS) scores were assessed and compared to baseline at 1, 3, 6 months, and annually after treatment.Results: The mean reported subjective percentage improvement across all 216 treated hips was 30.2%.The mean OHS change was 6.4 points improved (p<0.001).The NPS scores from baseline to post treatment decreased from 4.5 to 3.3 (p<0.001).Twelve AEs were reported, none of which were serious or persisting.Patients ≤ 55 years old were substantially more likely to report improvement on the OHS [OR: 11.1 (1.6-77.8)]and also more likely to report greater than 50% improvement on the subjective percentage improvement scale [OR: 2.8 (1.2-6.7)].Conclusion: The present study of BMC injections for hip OA demonstrated encouraging results for improved outcomes with no significant complications.We found that patients younger than 55 years old were more likely to report improvement on the OHS and subjective percentage improvement scales.Further study with randomized trials is warranted to confirm the reported results.